TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06385509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jatenzo
Description: 237 mg JATENZO twice daily
Study: NCT06261827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham treatment
Description: Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200-ppm NO
Description: NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
Study: NCT06468592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tilted insertion of implants
Description: Using osteotomes, implants are inserted and tilted from 30° to 45° into the palatal direction from the maxillary sinus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Straight insertion of implants
Description: The implants are inserted in an axial direction into the maxillary sinus according to Summers' traditional technique.
Study: NCT05468697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
Study: NCT05972109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace SSB sales ban
Description: Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace SSB sales ban
Description: Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.
Study: NCT05544708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Engagement Intervention
Description: Train for, recruit participants into, and lead a 12-week lifestyle intervention delivered via weekly group meetings
Study: NCT05178069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: : Placebo for Probiotic
Description: Capsule manufactured without active ingredients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus GG
Description: Probiotic nutritional supplement; Lactobacillus Rhamnosus G
Study: NCT05445102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect
Description: after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
Study: NCT06302569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Enfortumab Vedotin
Description: * Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab are eligible for up to 1 year of additional pembrolizumab (second course) upon experiencing disease progression.~* Enfortumab Vedotin will be given for a maximum of 3 cycles on day 1 and day 3 each 3 weeks. EV treatment could be re-started in case of Progressive Disease RECIST v1.1 during pembrolizumab monotherapy treatment.
Study: NCT05372354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days
Study: NCT05012462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1500
Description: The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1600
Description: The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors Bioelectrical Impedance, Photoplethysmography (PPG) Amplitude, ECG Amplitude and Skin Temperature. A combination of these parameters is represented by a single number known as the Relative Index value.
Study: NCT05293093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program
Description: a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
Study: NCT05372354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT05509530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-BCMA/GPRC5D CAR-T CELL
Description: anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy
Study: NCT04845867

Intervention type: DEVICE
Intervention: ISAR-M THYRO
Description: A diagnostic device for early detection of haemorrhage following thyroid surgery
Study: NCT05111327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured guideline
Description: Students in the intervention group will receive more learning materials before study. The structured guideline will be used to facilitate students' learning in simulation by the facilitator.
Study: NCT06042543

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening with HPV test
Description: Women aged 25-49 yrs will be screened with a validated HPV test. They will also provide urine samples for HPV test. Women HPV positive in either sample will be referred to colposcopy for disease ascertainment.
Study: NCT05671341

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Tandem walking test, Tandem Stance test, Activity-specific Balance Confidence Parkinson's Disease Quality of Life-8 N/L ratio Tinetti Balance Test UPDRS

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Tandem walking test, Tandem Stance test, Activity-specific Balance Confidence Parkinson's Disease Quality of Life-8 N/L ratio Tinetti Balance Test UPDRS
Study: NCT04891757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHD-286
Description: FHD-286 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHD-286
Description: FHD-286 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHD-286
Description: FHD-286 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Cytarabine
Description: LDAC administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine administered intravenously
Study: NCT06583187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coloring a mandala picture
Description: In the study, the experimental group was taken to their room on the day they came for circumcision and then had them paint mandalas. The coloring books chosen for mandala painting were determined to be appropriate for the age group of the children. The child was given a book and was given the freedom to paint the figures they wanted. Care was taken to ensure that the environment was quiet so that the child would be comfortable and calm. Care was taken to ensure that the crayons used in mandala painting did not contain carcinogenic substances and were anti-allergic.
Study: NCT04899362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China
Description: The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous blood collection
Description: Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dCA measurement
Description: Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
Study: NCT05005468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is given on the first day of each cycle, intravenous drip.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib is administered orally, once a day.
Study: NCT05700526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft
Description: Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft
Description: Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Routine preparation of bone graft according to standard protocols
Description: The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preparation of bone graft with virtual bone-matching and GSIs
Description: The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy
Description: The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Corrective osteotomy
Description: The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
Study: NCT05794126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1
Description: Soft multifocal hydrogel contact lens for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2
Description: Soft multifocal silicone hydrogel contact lens for 15 minutes.
Study: NCT05921539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid hydrodilatation
Description: ultrasound-guided steroid hydrodilatation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroid hydrodilatation
Description: ultrasound-guided steroid hydrodilatation
Study: NCT05487950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban group
Description: Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
Study: NCT05580250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.
Study: NCT06406738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using High Reality Simulator
Description: Using High Reality Simulator will perform newborn first-care.
Study: NCT05921539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axillary nerve injection
Description: ultrasound-guided axillary nerve injection
Study: NCT05541107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT2203
Description: oral lipid nanocrystal amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT2203
Description: oral lipid nanocrystal amphotericin B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Intravenous Amphotericin B
Study: NCT06538194

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
Study: NCT04899219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 40 mg
Description: ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470 40 mg
Description: ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
Study: NCT05483569

Intervention type: OTHER
Group type: OTHER
Intervention: Complex Decongestive Physiotherapy
Description: Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Diaphragmatic Breathing Exercises
Description: Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Release Technique
Description: Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
Study: NCT05615428

Intervention type: DIAGNOSTIC_TEST
Intervention: LS-ratio
Description: Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
Study: NCT06651216

Intervention type: OTHER
Intervention: Stool analysis
Description: Analysis of infant fecal microbiota

Intervention type: OTHER
Intervention: Stool analysis
Description: Analysis of infant fecal microbiota

Intervention type: OTHER
Intervention: breast milk analysis
Description: Analysis of the effect of breast milk miRNAs on infant fecal microbiota
Study: NCT06002828

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires